Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

17

Revenue 2017

Stelara

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Stelara was produced by Johnson & Johnson.

J&J inks $6.5bn all-cash deal to acquire Momenta

J&J inks $6.5bn all-cash deal to acquire Momenta

J&J already has high stakes in the autoimmune disease market, with some of its existing products, including psoriasis med Stelara (ustekinumab), already reaching blockbuster status.

J&J splashes $750m on anti-inflammatory drug bermekimab

J&J splashes $750m on anti-inflammatory drug bermekimab J&J already has high stakes in the anti-inflammatory market, with its blockbuster IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab) and follow-up Tremfya (guselkumab). ... The therapy is a follow-up to its older blockbuster Stelara, which is facing

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial

UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial This includes a recent phase 3 BE VIVID study comparing the drug to Johnson &Johnson’s Stelara (ustekinumab), which bimekizumab also demonstrated superiority over.

Janssen files Tremfya for psoriatic arthritis in Europe

Janssen files Tremfya for psoriatic arthritis in Europe First approved in Europe two years ago, Tremfya (guselkumab) is the follow-up to J&J’s IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab), which is facing increased competition across ... of Stelara – which made $4.66bn in the first three

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal showed it was better at clearing skin than placebo and Johnson &Johnson’s big-selling Stelara (ustekinumab) product.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics